News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), Wednesday announced positive efficacy outcome for third-line treatment in its Phase 2 clinical trial of THIO combined with the immune checkpoint inhibitor cemiplimab for the treatment of non-small cell lung cancer or NSCLC, the most common type of lung cancer.
Under the study, the overall response rate was 38 percent among the NSCLC patients who had failed treatment with immune checkpoint inhibitors.
The company stated that THIO-101 trial is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment.
Currently, MAIA's stock is trading at $1.6, up 8.11% on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
